As we have informed here, the Helsinn Group has closed a financing agreement with Oberland Capital Management. In this sense, VISCHER has advised Oberland Capital Management on its financing agreement with the Ticino based group.
Tags :Helsinn Group
Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic
BridgeBio Pharma, through its affiliate QED Therapeutics, and Helsinn Group announced a global collaboration and licensing agreement to further develop and commercialize QED Therapeutics’ FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except